PMID- 18077168
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20181201
IS  - 0960-9776 (Print)
IS  - 0960-9776 (Linking)
VI  - 17
IP  - 3
DP  - 2008 Jun
TI  - Effectively nursing patients receiving aromatase inhibitor therapy.
PG  - 227-38
AB  - Inhibiting estrogen production is a common means of preventing breast cancer 
      recurrence. The aromatase inhibitors (AIs) are becoming the preferred treatment 
      over tamoxifen as adjuvant therapy for postmenopausal women with 
      hormone-sensitive early breast cancer. Like all adjuvant therapies, AIs have 
      adverse events (AEs) associated with their use, many of which resemble symptoms 
      common to menopause. Because of the greater efficacy of AIs in preventing breast 
      cancer recurrence over tamoxifen, these AEs may be considered tolerable by many 
      patients and often can be effectively managed and/or prevented. Educating 
      patients about anticipated AEs may help them understand, accept, and cope with 
      these AEs. This article reviews the AEs associated with different adjuvant AI 
      treatments and highlights some strategies to manage them effectively. It also 
      highlights the importance of patient education regarding AI therapy and 
      involvement in treatment decisions, which may lead to better long-term adherence 
      and ultimately to better outcomes.
FAU - Wengstrom, Y
AU  - Wengstrom Y
AD  - Division of Nursing, Department of Neurobiology, Care Science and Society, 
      Karolinska Institutet, 23300, 141 83 Huddinge, Sweden. yvonne.wengstrom@ki.se
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20080220
PL  - Netherlands
TA  - Breast
JT  - Breast (Edinburgh, Scotland)
JID - 9213011
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Aromatase Inhibitors)
RN  - 0 (Lubricants)
RN  - 0 (Nitriles)
RN  - 0 (Triazoles)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 2Z07MYW1AZ (Anastrozole)
SB  - IM
MH  - Anastrozole
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Aromatase Inhibitors/*adverse effects/*therapeutic use
MH  - Arthralgia/chemically induced
MH  - Atrophy
MH  - Breast Neoplasms/*drug therapy/epidemiology/*nursing
MH  - Cardiovascular Diseases/epidemiology
MH  - Comorbidity
MH  - Female
MH  - Hot Flashes/chemically induced
MH  - Humans
MH  - Lubricants/therapeutic use
MH  - Neoplasm Recurrence, Local/prevention & control
MH  - Nitriles/therapeutic use
MH  - Patient Education as Topic
MH  - Quality of Life
MH  - Tamoxifen/therapeutic use
MH  - Triazoles/therapeutic use
MH  - Vagina/pathology
MH  - Weight Gain/drug effects
RF  - 120
EDAT- 2007/12/14 09:00
MHDA- 2008/08/30 09:00
CRDT- 2007/12/14 09:00
PHST- 2007/10/12 00:00 [received]
PHST- 2007/11/01 00:00 [accepted]
PHST- 2007/12/14 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2007/12/14 09:00 [entrez]
AID - S0960-9776(07)00251-2 [pii]
AID - 10.1016/j.breast.2007.11.001 [doi]
PST - ppublish
SO  - Breast. 2008 Jun;17(3):227-38. doi: 10.1016/j.breast.2007.11.001. Epub 2008 Feb 
      20.